The company composed a letter addressed to global governments to harness competitiveness and innovation to navigate the current global trade economy.
Nicholas Jacobus
Advertisement
Articles by Nicholas Jacobus
The partnership boosts BOT+BAL immunotherapy, securing US biologics manufacturing and accelerating Phase III mCRC development globally.
Johnson & Johnson reinforces its long-term domestic investment strategy with a new $2 billion biologics facility in Wilson, North Carolina, further elevating the state’s role as a global life sciences hub.
Advertisement
Latest Updated Articles
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus LifesciencesPublished: January 15th 2026 | Updated:
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North CarolinaPublished: January 12th 2026 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
3
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
4
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
5